Food Allergy Market

DelveInsight’s ‘Food Allergy–Market Insights, Epidemiology, and Market Forecast—2032’ report deliver an in-depth understanding of the Food Allergy, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, Canada and China.

 

The Food Allergy market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Food Allergy symptoms market size from 2019 to 2032 segmented by nine major markets. The report also covers current Food Allergy symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • Canada
  • China

Study Period: 2019–2032

Food Allergy Disease Understanding and Treatment Algorithm

Food Allergy Overview

According to National Institute of Allergy and Infectious Diseases (NIAID), a food allergy is an adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food. Food allergens are the parts of food or ingredients within food (usually proteins) that are recognized by immune cells. When an immune cell binds to a food allergen, a reaction occurs that causes the symptoms of food allergy. “Allergy” and “allergic disease” refer to conditions that involve changes to the immune system. These immune system changes fall into two categories: Immunoglobulin E (IgE) mediated and Non-IgE-mediated.

 

The symptoms of food allergies range from mild discomfort to severe, life-threatening reactions, which require immediate medical intervention. Symptoms may be triggered in the skin (itching, redness, swelling), gastrointestinal tract (pain, vomiting, diarrhea, itching and swelling of oral cavity), respiratory tract (itching and swelling of the nose and throat, asthma), eyes (itching and swelling), and/or cardiovascular system (e.g. chest pain, abnormal heart rhythm).

 

The cause of food allergy can be functional genetic variants in the IL-12 receptor b1, Toll-like receptor 9, and thymic stromal lymphopoietin genes and even IL-4 gene polymorphism have been associated with an increased risk of food sensitization.

 

Diagnosis of a food allergy relies on patient history and physical exam. The most common diagnosis method for food allergy according to World Allergy Organization (WAO) include Skin prick tests (SPT), which is the preferred testing method in those patients with a history compatible with food allergies; double blind placebo-controlled food challenge (DBPCFC), which is the preferred test to diagnose food allergy; the in vitro diagnostics can help to identify cross-reactive allergens between pollen and foods, or foods and latex, and the atopy patch test (APT) is an epicutaneous skin test in which allergens commonly associated with IgE reactions can be used.

 

The treatment of food allergy relies on avoidance of the foods to which an individual is allergic, as therapeutic intervention (tertiary prevention) in patients with food allergy. Unfortunately, severe reactions such as anaphylaxis may occur despite best efforts in avoidance. Epinephrine is the first-line medication for the treatment of anaphylaxis. Additional medications include H1 and H2 antihistamines, corticosteroids, and prostaglandin synthetase inhibitors these drugs are only symptomatic, do not modify the natural course of the disease.

 

Treatment of food allergy is a rapidly changing landscape, with arguably, the most significant advancement in recent years, the transition of oral immunotherapy (OIT) to clinical practice. As an innovation, OIT is a phase of rapidly increasing demand, particularly for some allergens such as peanut, egg, and milk, which have substantial evidence of efficacy.

 

The Food Allergy market dynamics are anticipated to change in the coming years owing to the expected launch of emerging therapies by major key players in the treatment regime. The launch of various multiple-stage pipeline products will significantly revolutionize the Food Allergy market dynamics shortly. 

 

Food Allergy Diagnosis and Treatment 

It covers the details of conventional and current medical therapies and diagnosis available in the Food Allergy market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, Japan, Canada and China. 

 

The DelveInsight Food Allergy market report gives a thorough understanding of Food Allergy symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides food allergy treatment algorithms and treatment guidelines in the US, Europe, Japan, Canada and China. 

Food Allergy Epidemiology 

The epidemiology division’s Food Allergy symptoms provide insights about the historical and current patient pool and the forecasted trend for every nine major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Food Allergy epidemiology segmented as the Prevalent Cases of Food Allergy, Prevalent Cases of Food Allergy based on Etiology-specific factors, Age-specific Prevalence of Food Allergy. The report includes the prevalent Food Allergy scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, Canada and China from 2019 to 2032. 

Country Wise- Food Allergy Epidemiology 

The epidemiology segment also provides the Food Allergy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Canada and China. 

 

The total 7MM, Canada and China prevalent cases of Food Allergy were 285,039,654 in 2021. 

Food Allergy Drug Chapters 

The drug chapter segment of the Food Allergy report encloses the detailed analysis of food allergy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Food Allergy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Products detail in the report…

 

Food Allergy Emerging Drugs 

 

Ligelizumab: Novartis Pharmaceuticals

From December 10, 2021, Novartis Pharmaceuticals, will initiate a 52-week, multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) injection every 4 weeks (SCq4w) in participants with a medically confirmed diagnosis of IgE-mediated peanut allergy. The participants will be randomized to ligelizumab 240 mg, Ligelizumab 120 mg, or placebo (5 treatment arms, randomization ratio of 2:2:2:2:1) for the double-blind placebo-controlled treatment period (up to Week 12). 

 

The primary outcome measure includes the proportion of participants who can tolerate a single dose of ≥ 600 mg (1044 mg cumulative tolerated dose) of peanut protein without dose-limiting symptoms at Week 12. The study will enroll 486 participants and get completed by May, 2025.

Products detail in the report…

Food Allergy Market Outlook

The Food Allergy market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Food Allergy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology. 

 

This segment gives a thorough detail of Food Allergy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

 

According to DelveInsight, Food Allergy market in 7MM, Canada and China is expected to change in the study period 2019–2032.

 

Key Findings

This section includes a glimpse of the Food Allergy market in 7MM, Canada and China. The market size of Food Allergy was found to be USD 2,028.97 million in 2021. 

 

The United States Market Outlook

This section provides a total of Food Allergy market size and market size by therapies in the United States. 

 

The United States accounts for the highest market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), Japan, Canada and China. 

 

EU-5 Countries: Market Outlook

The total Food Allergy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook 

The total Food Allergy market size and market size by therapies in Japan are mentioned. 

 

Canada Market Outlook 

The total Food Allergy market size and market size by therapies in Canada are mentioned. 

 

China Market Outlook 

The total Food Allergy market size and market size by therapies in China are also mentioned. 

Food Allergy Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers Food Allergy market uptake by drugs, patient uptake by therapies, and drug sales. 

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Food Allergy Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Food Allergy key players involved in developing targeted therapeutics. 

 

Major players Ligelizumab (Novartis Pharmaceuticals), Viaskin Peanut (DBV Technologies), INP20 (InnoUp Farma S.L.), Omalizumab (Genentech, Inc. /Novartis Pharmaceuticals/Rho Federal Systems Division, Inc.) etc being assessed as potential therapies to be available in the market in the coming future.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Food Allergy emerging therapies.

KOL Views 

To keep up with current market trends, we take KOLs and SME’s opinion working Food Allergy domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or Food Allergy market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs. 

Competitive Intelligence Analysis 

We perform a Competitive and Market Intelligence analysis of the Food Allergy Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Food Allergy explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Food Allergy epidemiology and treatment in the 7MM, Canada and China
  • Additionally, an all-inclusive account of both the current and emerging therapies for Food Allergy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Food Allergy market; historical and forecasted is included in the report, covering drug outreach in the 7MM, Canada and China
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Food Allergy market

Report Highlights

  • In the coming years, Food Allergy market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Food Allergy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Food Allergy. The launch of emerging therapies will significantly impact the Food Allergy market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Food Allergy
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Food Allergy Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Food Allergy Pipeline Analysis
  • Food Allergy Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Food Allergy Report Key Strengths

  • 11 Years Forecast
  • 7MM, Canada and China Coverage 
  • Food Allergy Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake

Food Allergy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Food Allergy Market share (%) distribution in 2019, and how would it look in 2032?
  • What would be the Food Allergy total market Size as well as market Size by therapies across the 7MM, Canada and China during the forecast period (2019–2032)?
  • What are the market’s key findings across 7MM, Canada and China, and which country will have the largest Food Allergy market Size during the forecast period (2019–2032)?
  • At what CAGR, the Food Allergy market is expected to grow by 7MM, Canada and China during the forecast period (2019–2032)?
  • What would be the Food Allergy market outlook across the 7MM, Canada and China during the forecast period (2019–2032)?
  • What would be the Food Allergy market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Food Allergy?
  • What is the historical Food Allergy patient pool in nine major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, Canada and China?
  • What would be the forecasted patient pool of Food Allergy in nine major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, Canada and China?
  • What will be the growth opportunities in the 7MM, Canada and China concerning the patient population about Food Allergy?
  • Out of all 7MM, Canada and China countries, which country would have the highest prevalent Food Allergy population during the forecast period (2019–2032)?
  • At what CAGR is the population expected to grow by 7MM, Canada and China during the forecast period (2019–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Food Allergy?
  • What are the current treatment guidelines for treating Food Allergy in the USA, Europe, Japan, Canada and China?
  • What are the Food Allergy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Food Allergy?
  • How many therapies are developed by each company for the treatment of Food Allergy?
  • How many emerging therapies are in the mid-stage and late development stages to treat Food Allergy?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Food Allergy therapies? 
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Food Allergy and their status?
  • What are the key designations that have been granted for the emerging therapies for Food Allergy?
  • What are the global historical and forecasted markets of Food Allergy?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Food Allergy market
  • To understand the future market competition in the Food Allergy market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Food Allergy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), Japan, Canada and China
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Food Allergy market
  • To understand the future market competition in the Food Allergy market

1. Key Insights

2. Report Introduction

3. Food allergy Market Overview at a Glance

3.1. Market Share (%) Distribution of Food allergy in 2019

3.2. Market Share (%) Distribution of Food allergy in 2032

4. Executive Summary of Food allergy

5. Disease Background and Overview

5.1. Introduction

5.2. Etiology

5.3. Clinical Manifestations

5.4. Subtypes of Food Allergy

5.5. Diagnosis

6. Management and Treatment

6.1. Guidelines

6.2. American Guidelines for the Diagnosis and Management of Food allergies

6.3. The European Academy of Allergy and Clinical Immunology (EAACI) Guidelines

6.4. Japanese Guidelines for Food allergies

6.4.1. Symptom Severity and Treatment

6.4.1.1. Grading symptom severity

6.4.1.2. Treatment based on symptom severity

6.4.1.3. Evaluation of organ-specific symptoms

6.4.2. Management of Anaphylaxis in a Health Care Setting

6.4.2.1. Confirmation of vital signs

6.4.2.2. Ensuring staff and treatment by a team

6.4.2.3. Intramuscular injection of adrenaline

6.4.2.4. Body position of the anaphylaxis patients

6.4.2.5. Administration of oxygen

6.4.2.6. Securing the intravenous infusion route and rapid rehydration

6.4.2.7. Cessation of respiration

6.4.2.8. Measurement of vital signs: Re-evaluation

6.4.3. Contraindication of adrenaline

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. 7MM, Canada and China Total Prevalent Patient Population of Food allergy

7.3. Assumption and Rationale

7.4. The United States

7.4.1. Prevalent cases of Food allergy in the United States

7.4.2. Prevalent Cases of Food allergy based on Etiology-specific factors in the United States

7.4.3. Age-specific Prevalence of Food allergy in the United States

7.5. EU5

7.5.1. Prevalent cases of Food allergy in the EU5

7.5.2. Prevalent Cases of Food allergy based on Etiology-specific factors in the EU5

7.5.3. Age-specific Prevalence of Food allergy in the EU5

7.6. Japan

7.6.1. Prevalent cases of Food allergy in Japan

7.6.2. Prevalent Cases of Food allergy based on Etiology-specific factors in Japan

7.6.3. Age-specific Prevalence of Food allergy in Japan

7.7. Canada

7.7.1. Prevalent cases of Food allergy in Canada

7.7.2. Prevalent Cases of Food allergy based on Etiology-specific factors in Canada

7.7.3. Age-specific Prevalence of Food allergy in Canada

7.8. China

7.8.1. Prevalent cases of Food allergy in China

7.8.2. Prevalent Cases of Food allergy based on Etiology-specific factors in China

7.8.3. Age-specific Prevalence of Food allergy in China

8. Patient Journey 1

9. Patient Journey 2

10. Marketed Therapies

10.1. Palforzia: Aimmune Therapeutics, Inc.

10.1.1. Drug Description

10.1.2. Other Development Information

10.1.3. Safety and Efficacy

10.1.4. Product Profile

11. Emerging Therapies

11.1. Ligelizumab: Novartis Pharmaceuticals

11.1.1. Drug Descriptions

11.1.2. Clinical Development

11.1.3. Clinical Trials Information

11.1.4. Product Profile

11.2. Viaskin Peanut: DBV Technologies

11.2.1. Drug Descriptions

11.2.2. Other Developmental Activities

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Product Profile

11.3. INP20: InnoUp Farma S.L.

11.3.1. Drug Descriptions

11.3.2. Clinical Development

11.3.3. Clinical Trials Information

11.3.4. Safety and Efficacy

11.3.5. Product Profile

11.4. CNP-201: COUR Pharmaceutical Development Company Inc.

11.4.1. Drug Descriptions

11.4.2. Clinical Development

11.4.3. Clinical Trials Information

11.4.4. Product Profile

11.5. VE416: Vedanta Biosciences, Inc.

11.5.1. Drug Descriptions

11.5.2. Clinical Development

11.5.3. Clinical Trials Information

11.5.4. Product Profile

11.6. Dupilumab: Regeneron Pharmaceuticals

11.6.1. Drug Descriptions

11.6.2. Other Developmental Activities

11.6.3. Clinical Development

11.6.4. Clinical Trials Information

11.6.5. Product Profile

11.7. Omalizumab: Genentech, Inc. /Novartis Pharmaceuticals/Rho Federal Systems Division, Inc.

11.7.1. Drug Descriptions

11.7.2. Other Development Information

11.7.3. Clinical Development

11.7.4. Clinical Trials Information

11.7.5. Safety and Efficacy

11.7.6. Product Profile

11.8. ADP101: Alladapt Immunotherapeutics, Inc.

11.8.1. Drug Descriptions

11.8.2. Clinical Development

11.8.3. Clinical Trials Information

11.8.4. Product Profile

11.9. CA002: Camallergy

11.9.1. Drug Description

11.9.2. Other development activity

11.9.3. Clinical Development

11.9.4. Clinical Trials Information

11.9.5. Safety and Efficacy

11.9.6. Product profile

12. Food allergy: 7MM, Canada and China Market Analysis

12.1. Key Findings

12.2. Market Size of Food allergy in 7MM, Canada and China

12.3. Market Size of Food allergy by Therapies

13. Market Outlook

13.1. United States Market Size

13.1.1. Total Market Size of Food allergy in the United States

13.1.2. Market Size of Food allergy by Therapies in the United States

13.2. EU-5 Market Size

13.2.1. Total Market size of Food allergy in the EU5

13.2.2. Market Size of Food allergy by Therapies in the EU5

13.3. Japan

13.3.1. Total Market size of Food allergy in Japan

13.3.2. Market Size of Food allergy by Therapies in Japan

13.4. Canada

13.4.1. Total Market size of Food allergy in Canada

13.4.2. Market Size of Food allergy by Therapies in Canada

13.5. China

13.5.1. Total Market size of Food allergy in China

13.5.2. Market Size of Food allergy by Therapies in China

14. KOL Views

15. Unmet Needs

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Table

Table 1: Summary of Food allergy, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Classification of Food Allergies

Table 3: Total Prevalent Patient Population of Food allergy in the 7MM, Canada and China (2019 –2032)

Table 4: Prevalent cases of Food allergy in the United States (2019–2032)

Table 5: Prevalent Cases of Food allergy based on Etiology-specific factor in the United States (2019–2032)

Table 6: Age-specific Prevalence of Food allergy in the United States (2019–2032)

Table 7: Prevalent cases of Food allergy in the EU5 (2019–2032)

Table 8: Prevalent Cases of Food allergy based on Etiology-specific factor in the EU5 (2019–2032)

Table 9: Age-specific Prevalence of Food allergy in the EU5 (2019–2032)

Table 10: Prevalent cases of Food allergy in Japan (2019–2032)

Table 11: Prevalent Cases of Food allergy based on Etiology-specific factors in Japan (2019–2032)

Table 12: Age-specific Prevalence of Food allergy in Japan (2019–2032)

Table 13: Prevalent cases of Food allergy in Canada (2019–2032)

Table 14: Prevalent Cases of Food allergy based on Etiology-specific factors in Canada (2019–2032)

Table 15: Age-specific Prevalence of Food allergy in Canada (2019–2032)

Table 16: Prevalent cases of Food allergy in China (2019–2032)

Table 17: Prevalent Cases of Food allergy based on Etiology-specific factors in China (2019–2032)

Table 18: Age-specific Prevalence of Food allergy in China (2019–2032)

Table 19: Ligelizumab (QGE031), Clinical Trial Description, 2022

Table 20: Viaskin Peanut, Clinical Trial Description, 2022

Table 21: INP20, Clinical Trial Description, 2022

Table 22: CNP-201, Clinical Trial Description, 2022

Table 23: VE416, Clinical Trial Description, 2022

Table 24: Dupilumab, Clinical Trial Description, 2022

Table 25: Omalizumab, Clinical Trial Description, 2022

Table 26: ADP101, Clinical Trial Description, 2022

Table 27: CA002, Clinical Trial Description, 2022

Table 28: 7 Major Market Size of Food allergy in USD Million (2019–2032)

Table 29: 7MM, Canada and China Market Size of Food allergy by Therapies in USD Million (2019–2032)

Table 30: The United States Market Size of Food allergy in USD Million (2019–2032)

Table 31: The United States Market Size of Food allergy by Therapies in USD Million (2019–2032)

Table 32: The EU5 Market Size of Food allergy in USD Million (2019–2032)

Table 33: The EU5 Market Size of Food allergy by Therapies in USD Million (2019–2032)

Table 34: Japan Market Size of Food allergy in USD Million (2019–2032)

Table 35: Japan Market Size of Food allergy by Therapies in USD Million (2019–2032)

Table 36: Canada Market Size of Food allergy in USD Million (2019–2032)

Table 37: Canada Market Size of Food allergy by Therapies in USD Million (2019–2032)

Table 38: China Market Size of Food allergy in USD Million (2019–2032)

Table 40: China Market Size of Food allergy by Therapies in USD Million (2019–2032)

List of Figures

Figure 1: Immune Cell Function

Figure 2: Total Prevalent Population of Food allergy in the 7MM, Canada and China (2019–2032)

Figure 3: Prevalent cases of Food allergy in the United States (2019–2032)

Figure 4: Prevalent Cases of Food allergy based on Etiology-specific factor in the United States (2019–2032)

Figure 5: Age-specific Prevalence of Food allergy in the United States (2019–2032)

Figure 6: Prevalent cases of Food allergy in the EU5 (2019–2032)

Figure 7: Prevalent Cases of Food allergy based on Etiology-specific factor in the EU5 (2019–2032)

Figure 8: Age-specific Prevalence of Food allergy in the EU5 (2019–2032)

Figure 9: Prevalent cases of Food allergy in Japan (2019–2032)

Figure 10: Prevalent Cases of Food allergy based on Etiology-specific factors in Japan (2019–2032)

Figure 11: Age-specific Prevalence of Food allergy in Japan (2019–2032)

Figure 12: Prevalent cases of Food allergy in Canada (2019–2032)

Figure 13: Prevalent Cases of Food allergy based on Etiology-specific factors in Canada (2019–2032)

Figure 14: Age-specific Prevalence of Food allergy in Canada (2019–2032)

Figure 15: Prevalent cases of Food allergy in China (2019–2032)

Figure 16: Prevalent Cases of Food allergy based on Etiology-specific factors in China (2019–2032)

Figure 17: Age-specific Prevalence of Food allergy in China (2019–2032)

Figure 18: 7MM, Canada and China Market Size of Food allergy in USD Million (2019–2032)

Figure 19: 7MM, Canada and China Market Size of Food allergy by Therapies in USD Million (2019–2032)

Figure 20: Market Size of Food allergy in the United States, USD Million (2019–2032)

Figure 21: The United States Market Size of Food allergy by Therapies in USD Million (2019–2032)

Figure 22: Market Size of Food allergy in the EU5, USD Million (2019–2032)

Figure 23: The EU5 Market Size of Food allergy by Therapies in USD Million (2019–2032)

Figure 24: Market Size of Food allergy in the Japan, USD Million (2019–2032)

Figure 25: Japan Market Size of Food allergy by Therapies in USD Million (2019–2032)

Figure 26: Market Size of Food allergy in Canada, USD Million (2019–2032)

Figure 27: Canada Market Size of Food allergy by Therapies in USD Million (2019–2032)

Figure 28: Market Size of Food allergy in China, USD Million (2019–2032)

Figure 29: China Market Size of Food allergy by Therapies in USD Million (2019–2032)

Aimmune Therapeutics, Inc.
Novartis Pharmaceuticals
DBV Technologies
InnoUp Farma S.L.
COUR Pharmaceutical Development Company Inc.
Vedanta Biosciences, Inc.
Regeneron Pharmaceuticals
Genentech, Inc.
Rho Federal Systems Division, Inc.
Alladapt Immunotherapeutics, Inc.
Camallergy

 

Forward to Friend

Need A Quote